One of many sessions showing #AUA24 endorsing this non EBM treatment to the point they discuss focal as something to add to your armamentarium rather than get evidence to support its use, FDA approval, payer and guideline support, and most importantly, patient benefit.

Come on…

Daniel E Spratt Matt M Brendon Stiles SEER makes me think of One Night Ultimate Werewolf (highly recommended BTW).

I guess the picture works for both!

🌟 Just 1 Week to Go Until #APCCC24 ! 🌟

🚀 Are you ready for the most anticipated oncology conference of the year? APCCC 2024 kicks off next week, April 25-27, in the stunning city of Lugano🇨🇭!

With our hybrid format, don't miss your chance to be part of this transformative…

Shameless plug of our Young & Early Career investigators programme: eortc.org/early-career/
Get in touch with EORTC !

Brendon Stiles My friend Brendon Stiles, you are focusing on the mouse data but not RCTs...

In humans, SABR decreases progression, sometimes increases OS. Even the one negative trial (BR-002) had a HR <1.

BTW still some space in the table any positive surgical trials 😉

Sexual structure sparing for #ProstateCancer radiotherapy: a systematic review. #BeyondTheAbstract . Jennifer Le Guévelou CentreEugèneMarquis discusses work published in European Urology Oncology. #ReadNow > bit.ly/3UGphSR Paul Sargos Supiot Stéphane Ploussard Guillaume

We had a discussion yesterday on the value of local RT in high volume PCa based on the PFS gains seen in STAMPEDE and PEACE1 and many argued not to do so, but I do not get that point if you take into account the low cost and benefits in comparison with the drugs Alberto Bossi

📢🔈And then on the other hand... just breaking this month - jamanetwork.com/journals/jama/… - 19 of 46 cancer drugs (41%) granted accelerated FDA approval from 2013-2017 did not improve overall survival in confirmatory trials; 🧐 #radonc

Happy to share our work describing patterns of nodal recs (PSMA) after prostate-only RT in HRCaP.
✓ Pelvic caudal border definition varies - RTOG v PIVOTAL v NRG v GFRU!
Vedang Murthy Priyamvada Maitre Rishika Mody TMC Radiation Oncology Clinical Oncology

Diagnostic CT-Enabled Planning (DART) for palliative RT
👉 Time in center reduced from 4.7h to 0.4h
👉 Highly relevant study to reduce efforts for palliative patients while maintaining radiotherapy quality
👏 Melissa O'Neil Dr. David Palma and study team
redjournal.org/article/S0360-…

The latest version of the prostate cancer guidelines are now summarised and available. You have heard the rumours now read what we changed and why! European Urology European Association of Urology (EAU) Derya Tilki, MD authors.elsevier.com/c/1iwC714kplyy…

Tony Felefly Brendon Stiles M. Bolton Shankar Siva Absolutely! A pathologic complete response (pCR) is definitely not a reliable indicator of local control in radiation therapy, especially not just 10 weeks post-treatment for any disease site.

Other examples that come to mind include anal squamous cancer, where it's prudent to…

I am curious as to why this is considered “a huge win” for patients? #mmsm #oncopharm

If you are interested in the SUNSET paper, we added 2 dose distributions that might be helpful: one that illustrates where the PTV needed to be compromised, and one where it didn't.

A full dosimetry paper is coming later...

ENZA-p trial The Lancet Oncology
authors.elsevier.com/a/1iw3e5EIIgPd…
Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC.
Biomarker guided combination therapy works!
Better response depth/duration with no added tox. ANZUP NHMRC CTC Movember Australia St Vincent's Sydney

My public comment on MRD and going to speak later today at meeting
regulations.gov/comment/FDA-20…

Now published at npj Journals precision oncology:
nature.com/articles/s4169…

Happy to share the first preprint of the lab focusing on sarcomatoid urothelial #bladdercancer using patient-derived #organoids . Great effort led by our student Michele @MicGarioni with the help of our colleagues UniSpitalBaselCH Department of Biomedicine

Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment | Oncology | JAMA Oncology | JAMA Network Joy of academic medicine is to work with amazing students & mentees! ⁦Nicholas Verdini⁩ ⁦Erin Gillespie, MD MPH⁩ jamanetwork.com/journals/jamao…

No SUNSET on this ultracentral trial of 60 Gy in 8 fractions
<7% grade 3-5 AEs, ~90% local control
Online at: redjournal.org/article/S0360-…
Meredith Giuliani Benjamin Lok, MD Alex Louie MD, PhD Houda Bahig, MD PhD Andrea Bezjak Scott Bratman Dr. David Palma